Serveur d'exploration sur la maladie de Parkinson

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Injectable hydrogels for central nervous system therapy

Identifieur interne : 000036 ( Main/Exploration ); précédent : 000035; suivant : 000037

Injectable hydrogels for central nervous system therapy

Auteurs : Malgosia M. Pakulska [Canada] ; Brian G. Ballios [Canada] ; Molly S. Shoichet [Canada]

Source :

RBID : ISTEX:4F60E0798ECD636F45F6C44DADB807913D57B317

Abstract

Diseases and injuries of the central nervous system (CNS) including those in the brain, spinal cord and retina are devastating because the CNS has limited intrinsic regenerative capacity and currently available therapies are unable to provide significant functional recovery. Several promising therapies have been identified with the goal of restoring at least some of this lost function and include neuroprotective agents to stop or slow cellular degeneration, neurotrophic factors to stimulate cellular growth, neutralizing molecules to overcome the inhibitory environment at the site of injury, and stem cell transplant strategies to replace lost tissue. The delivery of these therapies to the CNS is a challenge because the bloodbrain barrier limits the diffusion of molecules into the brain by traditional oral or intravenous routes. Injectable hydrogels have the capacity to overcome the challenges associated with drug delivery to the CNS, by providing a minimally invasive, localized, void-filling platform for therapeutic use. Small molecule or protein drugs can be distributed throughout the hydrogel which then acts as a depot for their sustained release at the injury site. For cell delivery, the hydrogel can reduce cell aggregation and provide an adhesive matrix for improved cell survival and integration. Additionally, by choosing a biodegradable or bioresorbable hydrogel material, the system will eventually be eliminated from the body. This review discusses both natural and synthetic injectable hydrogel materials that have been used for drug or cell delivery to the CNS including hyaluronan, methylcellulose, chitosan, poly(N-isopropylacrylamide) and Matrigel.

Url:
DOI: 10.1088/1748-6041/7/2/024101


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title>Injectable hydrogels for central nervous system therapy</title>
<author>
<name sortKey="Pakulska, Malgosia M" sort="Pakulska, Malgosia M" uniqKey="Pakulska M" first="Malgosia M" last="Pakulska">Malgosia M. Pakulska</name>
</author>
<author>
<name sortKey="Ballios, Brian G" sort="Ballios, Brian G" uniqKey="Ballios B" first="Brian G" last="Ballios">Brian G. Ballios</name>
</author>
<author>
<name sortKey="Shoichet, Molly S" sort="Shoichet, Molly S" uniqKey="Shoichet M" first="Molly S" last="Shoichet">Molly S. Shoichet</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:4F60E0798ECD636F45F6C44DADB807913D57B317</idno>
<date when="2012" year="2012">2012</date>
<idno type="doi">10.1088/1748-6041/7/2/024101</idno>
<idno type="url">https://api.istex.fr/document/4F60E0798ECD636F45F6C44DADB807913D57B317/fulltext/pdf</idno>
<idno type="wicri:Area/Main/Corpus">002504</idno>
<idno type="wicri:Area/Main/Curation">002173</idno>
<idno type="wicri:Area/Main/Exploration">000036</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a">Injectable hydrogels for central nervous system therapy</title>
<author>
<name sortKey="Pakulska, Malgosia M" sort="Pakulska, Malgosia M" uniqKey="Pakulska M" first="Malgosia M" last="Pakulska">Malgosia M. Pakulska</name>
<affiliation wicri:level="4">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Chemical Engineering and Applied Chemistry, University of Toronto, 200 College Street, Toronto, ON M5S 3E5</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute of Biomaterials and Biomedical Engineering (IBBME), University of Toronto, 164 College Street, Room 407, Toronto, ON M5S 3G9</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Ballios, Brian G" sort="Ballios, Brian G" uniqKey="Ballios B" first="Brian G" last="Ballios">Brian G. Ballios</name>
<affiliation wicri:level="4">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute of Medical Science, University of Toronto, 1 King's College Circle, Toronto, ON M5S 1A8</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Shoichet, Molly S" sort="Shoichet, Molly S" uniqKey="Shoichet M" first="Molly S" last="Shoichet">Molly S. Shoichet</name>
<affiliation wicri:level="4">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Chemical Engineering and Applied Chemistry, University of Toronto, 200 College Street, Toronto, ON M5S 3E5</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Institute of Biomaterials and Biomedical Engineering (IBBME), University of Toronto, 164 College Street, Room 407, Toronto, ON M5S 3G9</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="4">
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Chemistry, University of Toronto, 80 St. George Street, Toronto, ON M5S 3H6</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName>
<settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country wicri:rule="url">Canada</country>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">Biomedical Materials</title>
<idno type="ISSN">1748-6041</idno>
<idno type="eISSN">1748-605X</idno>
<imprint>
<publisher>IOP Publishing</publisher>
<date type="published" when="2012-04">2012-04</date>
<biblScope unit="volume">7</biblScope>
<biblScope unit="issue">2</biblScope>
</imprint>
<idno type="ISSN">1748-6041</idno>
</series>
<idno type="istex">4F60E0798ECD636F45F6C44DADB807913D57B317</idno>
<idno type="DOI">10.1088/1748-6041/7/2/024101</idno>
<idno type="href">http://stacks.iop.org/BMM/7/024101</idno>
<idno type="ArticleID">bmm407743</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">1748-6041</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass></textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract">Diseases and injuries of the central nervous system (CNS) including those in the brain, spinal cord and retina are devastating because the CNS has limited intrinsic regenerative capacity and currently available therapies are unable to provide significant functional recovery. Several promising therapies have been identified with the goal of restoring at least some of this lost function and include neuroprotective agents to stop or slow cellular degeneration, neurotrophic factors to stimulate cellular growth, neutralizing molecules to overcome the inhibitory environment at the site of injury, and stem cell transplant strategies to replace lost tissue. The delivery of these therapies to the CNS is a challenge because the bloodbrain barrier limits the diffusion of molecules into the brain by traditional oral or intravenous routes. Injectable hydrogels have the capacity to overcome the challenges associated with drug delivery to the CNS, by providing a minimally invasive, localized, void-filling platform for therapeutic use. Small molecule or protein drugs can be distributed throughout the hydrogel which then acts as a depot for their sustained release at the injury site. For cell delivery, the hydrogel can reduce cell aggregation and provide an adhesive matrix for improved cell survival and integration. Additionally, by choosing a biodegradable or bioresorbable hydrogel material, the system will eventually be eliminated from the body. This review discusses both natural and synthetic injectable hydrogel materials that have been used for drug or cell delivery to the CNS including hyaluronan, methylcellulose, chitosan, poly(N-isopropylacrylamide) and Matrigel.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
<region>
<li>Ontario</li>
</region>
<settlement>
<li>Toronto</li>
</settlement>
<orgName>
<li>Université de Toronto</li>
</orgName>
</list>
<tree>
<country name="Canada">
<region name="Ontario">
<name sortKey="Pakulska, Malgosia M" sort="Pakulska, Malgosia M" uniqKey="Pakulska M" first="Malgosia M" last="Pakulska">Malgosia M. Pakulska</name>
</region>
<name sortKey="Ballios, Brian G" sort="Ballios, Brian G" uniqKey="Ballios B" first="Brian G" last="Ballios">Brian G. Ballios</name>
<name sortKey="Pakulska, Malgosia M" sort="Pakulska, Malgosia M" uniqKey="Pakulska M" first="Malgosia M" last="Pakulska">Malgosia M. Pakulska</name>
<name sortKey="Shoichet, Molly S" sort="Shoichet, Molly S" uniqKey="Shoichet M" first="Molly S" last="Shoichet">Molly S. Shoichet</name>
<name sortKey="Shoichet, Molly S" sort="Shoichet, Molly S" uniqKey="Shoichet M" first="Molly S" last="Shoichet">Molly S. Shoichet</name>
<name sortKey="Shoichet, Molly S" sort="Shoichet, Molly S" uniqKey="Shoichet M" first="Molly S" last="Shoichet">Molly S. Shoichet</name>
<name sortKey="Shoichet, Molly S" sort="Shoichet, Molly S" uniqKey="Shoichet M" first="Molly S" last="Shoichet">Molly S. Shoichet</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000036 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000036 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:4F60E0798ECD636F45F6C44DADB807913D57B317
   |texte=   Injectable hydrogels for central nervous system therapy
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024